Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection

被引:51
作者
George G. Zhanel
机构
[1] University of Manitoba,Faculties of Medicine and Pharmacy
[2] Health Sciences Centre,Departments of Medicine and Microbiology
关键词
Levofloxacin; Streptococcus Pneumoniae; Lactam; Antimicrob Agent; Gatifloxacin;
D O I
10.1007/s11908-001-0056-x
中图分类号
学科分类号
摘要
When evaluating the efficacy of antibiotics for the treatment of respiratory tract infections, such as community acquired pneumonia and acute exacerbations of chronic bronchitis, assessment of clinical cure may not be the most relevant parameter, as it may not be related to microbiological eradication or to the minimum inhibitory concentration (MIC) of the infecting pathogen. It is more relevant to study the efficacy of the antibiotic in eradicating the bacterial pathogen, because this is frequently related to both the MIC of the pathogen and the antibiotic dosage regimen. Pharmacodynamics correlates the concentration of antibiotic in the blood or at the infection site with its biological effect against the organism (bacteriological eradication). For β-lactams, the pharmacodynamic parameter that best correlates with eradication is time (T) above MIC (T > MIC); for aminoglycosides and fluoroquinolones, it is the area under the curve at 24 hours (AUC24)-to-MIC ratio (AUC24/MIC). Knowledge of pharmacodynamics allows optimum use of antibiotics; in vitro models, animal models, and retrospective and prospective clinical trials have shown that the use of such knowledge optimizes bacteriological eradication and enhances patient outcome. In the future, pharmacodynamic studies will be used not only to assess optimal ways for antibiotics to eradicate resistant pathogens, but also to investigate the ability of antibiotics to prevent the development of resistance on therapy and to eradicate pathogens from colonizing sites.
引用
收藏
页码:29 / 34
页数:5
相关论文
共 80 条
[21]  
Goldstein FW(1997)Phamacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis J Antimicrob Chemother 40 45-57
[22]  
Zhanel GG(2000)Pharmacodynamics and pharmacokinetics of levofloxacin Chemother 46 6-14
[23]  
Hoban DJ(1999)Fluoroquinolones in Canada: A critical review Can J Infect Dis 10 207-238
[24]  
Harding GKM(2000)Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro dynamic model Antimicrob Agents Chemother 44 773-774
[25]  
Jacobs MR(2000)Comparison of fluoroquinolones based on pharmacokinetic/pharmacodynamic parameters Pharmacother 20 417-428
[26]  
Jacobs MR(1999)Antibiotic use in community practice: Assessing quantity, indications and appropriateness and its relationship to the development of antibiotic resistance Drugs 57 871-881
[27]  
Bajaksouzian S(1999)Prevalence of antibiotic resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study Antimicrob Agents Chemother 43 2504-2509
[28]  
Zilles A(1998)Prevalence of antibiotic resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antibiotic Surveillance Program Clin Infect Dis 27 764-770
[29]  
Andes D(1996)A multicentre collaborative study of the antimicrobial susceptibility of communityacquired, lower respiratory tract pathogens 1992–1993: the Alexander Project J Antimicrob Chemother 38 1-57
[30]  
Craig WA(1999)Acute otitis media: management and surveillance in the area of pneumococcal resistance, a report from the Drug Resistant Streptococcus pneumoniae Therapeutic Working Group Pediatr Infect Dis J 18 1-9